These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Do interventions provide additional benefit to drug treatment of acute coronary syndromes? A call for a reserved, watchful approach. Gulba DC Thromb Haemost; 1999 Aug; 82(2):953-61. PubMed ID: 10605809 [No Abstract] [Full Text] [Related]
4. [Role of antiplatelet agents in the treatment of ischemic cardiopathy]. Bonhorst D Rev Port Cardiol; 1989 Apr; 8(4):261-4. PubMed ID: 2534356 [TBL] [Abstract][Full Text] [Related]
5. Acute coronary syndromes: new developments in pharmacological treatment strategies. Gylys K; Gold M Crit Care Nurse; 2000 Apr; Suppl():3-14; quiz 15-6. PubMed ID: 11876169 [No Abstract] [Full Text] [Related]
6. API expert consensus document on management of ischemic heart disease. Association of Physicians of India J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697 [TBL] [Abstract][Full Text] [Related]
7. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
8. Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. Puma JA; Sketch MH J Am Osteopath Assoc; 2000 Nov; 100(11 Suppl):S8-12. PubMed ID: 11191119 [TBL] [Abstract][Full Text] [Related]
9. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
10. [Antiplatelets and anticoagulants in acute coronary syndromes: levels of evidence]. Páramo JA; García R; Rodríguez P; de Gaona ER Rev Med Univ Navarra; 2007; 51(1):23-7. PubMed ID: 17555117 [TBL] [Abstract][Full Text] [Related]
11. Medical therapy of unstable angina pectoris. Gottlieb SO; Flaherty JT Cardiol Clin; 1991 Feb; 9(1):89-98. PubMed ID: 1674228 [TBL] [Abstract][Full Text] [Related]
12. [Risk stratification in the acute coronary syndrome. Diabetes--a diagnostic dilemma]. Giannitsis E; Katus HA Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S211-4. PubMed ID: 17109251 [No Abstract] [Full Text] [Related]
14. The use of antithrombotic drugs in artery disease. Gallus AS Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934 [TBL] [Abstract][Full Text] [Related]
16. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
18. Management of acute coronary syndromes with emphasis on new information for the treatment of ST-segment elevation acute myocardial infarction. Lincoff AM J Invasive Cardiol; 2002 Feb; 14 Suppl A():1A-2A. PubMed ID: 11847401 [No Abstract] [Full Text] [Related]
19. Prevention of cardiovascular events after acute coronary syndrome. Wallentin L Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917 [TBL] [Abstract][Full Text] [Related]